A study in mice combining two inhibitor drugs for treatment of chronic myeloid leukemia (CML) has revealed potential for not only stopping the disease completely, but also significantly lowering the cost for treatment.
Scripps Health and The University of Texas MD Anderson Cancer Center have reached a partnership agreement to create Scripps MD Anderson Cancer Center, a comprehensive and clinically integrated cancer care program in San Diego that will provide adult cancer patients greater access to the most advanced oncology care available throughout Southern California.
The University of Texas MD Anderson Cancer Center presents it Making Cancer History® Seminar, 11:30 a.m. to 1 p.m. Wednesday, Sept. 21 at the Grand Hyatt Atlanta in Buckhead, 3300 Peachtree Rd. NE. MD Anderson cancer experts will discuss the institution’s mission to end cancer through the latest treatment, research, prevention and education strategies advanced by the Moon Shots Program, a comprehensive effort to rapidly reduce cancer deaths and transform patient care.
The University of Texas MD Anderson Cancer Center was awarded $19.1 million in research grants this week from the Cancer Prevention and Research Institute of Texas (CPRIT).
As with most cancers, triple-negative breast cancer (TNBC) cells have abnormal amounts of chromosomes or DNA copy number aberrations (CNAs) in their genomes. A new study used single cell sequencing technology to provide previously unknown details about how and when CNAs impact tumor formation and growth, information that may have significant implications for diagnosis and treatment.
The University of Texas MD Anderson Cancer Center brings its signature Making Cancer History® seminar to Austin, 11:30 a.m. to 1 p.m., Monday, Sept. 12, at the AT&T Executive Education and Conference Center, 1900 University Ave. Renowned experts from the nation’s No. 1 cancer center will share advances of the Moon Shots Program, a comprehensive initiative to significantly reduce cancer deaths and transform care.
The third edition of The MD Anderson Manual of Medical Oncology recently was published, offering detailed updates on the personalized multidisciplinary approach to cancer management and treatment of common and rare cancers pioneered by world-leading specialists at The University of Texas MD Anderson Cancer Center.
A study that indicates how advanced melanoma responds to an immunotherapy, published in Cancer Discovery, demonstrates a revolutionary approach from The University of Texas MD Anderson Moon Shots Program that relies on longitudinal sampling and deep molecular analyses to understand the dynamics of cancer response to treatment.
The 27th annual A Conversation With a Living Legend® in Dallas, Sept. 28 at the Hilton Anatole, will honor Kenneth H. Cooper, M.D., M.P.H., founder of The Cooper Clinic and The Cooper Institute.
Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center report in the journal Cancer Discovery.
Although it reads like European license plate number, a protein known as ZMYND8 has demonstrated its ability to block metastasis-linked genes in prostate cancer, according to a study at The University of Texas MD Anderson Cancer Center.
Up to 15 percent of colorectal cancers show a genetic mutation known as DNA mismatch repair deficiency, or dMMR. Until now, little has been known about how the mutation behaves in rectal cancer patients, what causes dMMR, and which treatments may be most effective.
Today, several of Space City’s best-known institutions — The University of Texas MD Anderson Cancer Center, the National Aeronautics and Space Administration (NASA) and ILC Dover — announced a partnership that brings the benefits of arts and science to pediatric cancer patients while increasing awareness of childhood cancer.
Hitachi Chemical Co., Ltd. and The University of Texas MD Anderson Cancer Center have entered into a four-year strategic alliance funded by Hitachi to help develop and evaluate the company’s Micro Cavity Array (MCA) Circulating Tumor Cell (CTC) system for the isolation of CTC that can be subjected to downstream molecular analyses.
Using an innovative approach to identify a cancer’s genetic vulnerabilities by more swiftly analyzing human tumors transplanted into mice, researchers have identified a new potential target for pancreatic cancer treatment, published online in Cell Reports.
The University of Texas MD Anderson Cancer Center will join institutions across the country in the inaugural national Cancer Moonshot Summit, convened at the request of Vice President Joe Biden, on June 29.
Early-stage breast cancer patients receiving a shorter course of whole breast radiation with higher radiation doses per fraction reported equivalent cosmetic, functional and pain outcomes over time as those receiving a longer, lower-dose per fraction course of treatment, according to researchers from The University of Texas MD Anderson Cancer Center.
In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified for stem cell transplants.
Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center today announced a new clinical research collaboration to evaluate innovative strategies for the potential use of Bristol-Myers Squibb’s immuno-oncology agents Opdivo (nivolumab) and Yervoy (ipilimumab) to treat early- and advanced-stage lung cancer patients.
Lung cancer patients with oliogometastases, defined as three or fewer sites of metastasis, may benefit from aggressive local therapy, surgery or radiation, after standard chemotherapy, according to research led by The University of Texas MD Anderson Cancer Center.
Advances that could change gynecologic cancer standard–of-care treatments are the centerpiece of key studies being presented by researchers from The University of Texas MD Anderson Cancer Center’s Department of Gynecologic Oncology and Reproductive Medicine at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO).
In the first-ever clinical trial for metastatic patients previously treated for the disease, research led by The University of Texas MD Anderson Cancer Center found that the immune checkpoint blockade nivolumab shows promise for the majority of patients with squamous cell carcinoma of the anal canal (SCCA).
The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug’s target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.
Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new research from The University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center brings its signature Making Cancer History® seminar to Raleigh, N.C., for the first time, 11:30 a.m. to 1 p.m., Wednesday, June 8, at the McKimmon Conference and Training Center, 1101 Gorman St. Renowned experts from the nation’s No. 1 hospital for cancer care will share recent developments in cancer research, care and prevention.
Researchers at The University of Texas MD Anderson Cancer Center have discovered mutations that may fuel early cancer growth in precancerous colorectal tissue from high-risk patients.
Ionis Pharmaceuticals, Inc.,and The University of Texas MD Anderson Cancer Center today announced the formation of a strategic alliance to discover and develop novel cancer therapeutics.
The University of Texas MD Anderson Cancer Center will receive $10.6 million in funding from the Cancer Prevention and Research Institute of Texas (CPRIT) for two collaborative studies targeting crucial issues in lung cancer.
A study comprised of 39 international institutions revealed significant new findings about adrenocortical carcinoma (ACC), a rare cancer with an often poor prognosis.
It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
The University of Texas MD Anderson Cancer Center fully supports new rules issued by the Food and Drug Administration (FDA) today to extend federal regulatory authority to all tobacco products, including electronic cigarettes, cigars, hookah and other previously unregulated tobacco products.
A study providing new information about neuropathic pain afflicting some 90 percent of cancer patients who have had nerve damage caused by tumors, surgery, chemotherapy or radiation indicates gene therapy as a possible treatment.
Small, non-coding molecules called microRNAs are known to play an important role in cancer development. Researchers now have shown their significance is greater than previously thought, a finding that could lead to new therapeutic approaches for the most common and deadly form of ovarian cancer.
A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by The University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, today announced that they signed a strategic alliance on a broad, multi-years program of clinical studies in cancer supportive and palliative care.
The University of Texas MD Anderson Children’s Cancer Hospital, in collaboration with local restaurants and businesses, will host a special prom for its pediatric cancer patients on Saturday, April 30 from 5 p.m. to 9 p.m.
Eight of The University of Texas MD Anderson Cancer Center’s top young researchers today were formally named Andrew Sabin Family Fellows at an event honoring their benefactor, Andrew Sabin, and representatives of the Andrew Sabin Family Foundation.
Scientists may have discovered a significant new diagnostic marker for liver cancer, according to a paper published in the April 18 online issue of Nature Cell Biology.
Researchers at The University of Texas MD Anderson Cancer Center have announced a new method for detecting DNA mutations in a single cancer cell versus current technology that analyzes millions of cells which they believe could have important applications for cancer diagnosis and treatment. The results are published in the April 18 online issue of Nature Methods.
A phase I study of the drug LOXO-101 appears to significantly reduce tumors in patients with varied types of genetically defined cancer, according to a study led by The University of Texas MD Anderson Cancer Center.
A rare malignancy known as squamous cell carcinoma of the anal canal (SCCA) is on the increase, and now researchers have reported results of the first-ever phase II clinical trial results for treatment with the immunotherapy drug nivolumab.
Waun Ki Hong, M.D., professor of Thoracic Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, has been selected as recipient of this year’s Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research by the American Association for Cancer Research (AACR).
The University of Texas MD Anderson Cancer Center and Saks Fifth Avenue will join forces April 27 at a cocktail and store preview event to celebrate the recent Saks Fifth Avenue move within the all-new Galleria III. Saks Fifth Avenue is contributing 100 percent of ticket sales and 10 percent of the evening’s store sales to benefit MD Anderson’s Moon Shots Program, an unprecedented effort to rapidly reduce deaths from cancer and transform care.
Long associated with liver cancer and non-Hodgkin’s lymphoma, a study from The University of Texas MD Anderson Cancer Center reveals for the first time that the hepatitis C virus (HCV) is associated with certain head and neck cancers.
Receptors for leptin, a protein hormone, may be associated with tumor recurrence in patients with renal cell carcinoma (RCC), providing further understanding about molecular links between obesity and RCC tumor formation and prognosis, according to a study at The University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center welcomed His Highness Sheikh Hamed Bin Zayed Al Nahyan, Chairman of the Crown Prince Court of Abu Dhabi, and His Excellency Mohamed Haji Al Khoori, Director General of the Khalifa Bin Zayed Al Nahyan Foundation, April 8 to celebrate the dedication of the Sheikh Zayed Bin Sultan Al Nahyan Building for Personalized Cancer Care.
TESARO, Inc., an oncology focused biopharmaceutical company, and the Institute for Applied Cancer Science at The University of Texas MD Anderson Cancer Center today announced an exclusive collaboration to discover and develop small molecule product candidates against undisclosed immuno-oncology targets.
The University of Texas MD Anderson Cancer Center’s Volunteer Endowment for Patient Support (VEPS), which funds patient-focused programs, celebrates its 25th anniversary this year.
The University of Texas MD Anderson Cancer Center brings its signature Making Cancer History® seminar to Austin, 11:30 a.m. to 1 p.m., Tuesday, April 19, at the AT&T Executive Education and Conference Center, 1900 University Ave.
A new breast cancer staging system developed by researchers at The University of Texas MD Anderson Cancer Center finds that incorporating tumor biology is a critical prognostic indicator for women who undergo neoadjuvant, or pre-surgical, therapy for breast cancer.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right